-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] In the morning news on August 5, the pharmaceutical sector of Hong Kong stocks ro.
As of 10:35, BeiGene rose by more than 11%, Innovent Bio and GenScript Biotechnology rose by more than 5%, and China Biopharmaceutical and CSPC Group followed su.
BeiGene: Up more than 11% As of 10:35, BeiGene increased by 105%, with a quotation of 1199 yuan, a turnover of 421 million, a turnover rate of 79%, and a loss in price-earnings (TT.
On the news, BeiGene released the US stock performance report for the second quarter of 2022 and the A-share semi-annual performance report on August The semi-annual report shows that in the first half of this year, the company achieved a total operating income of 21 billion yuan, a year-on-year decrease of 19%; the net profit attributable to owners of the parent company was still at a loss, reaching 664 billion yuan; the operating loss was 43 billion yuan, an increase over the same period last ye.
063 billion yu.
As for the reasons for the expansion of operating losses, the company stated that it was mainly due to the decline of 774 billion yuan in cooperation income and the exchange loss of 771 million yuan due to the appreciation of the US doll.
The former was mainly due to the same period last ye.
Partial revenue recognition for USD cooperative advanc.
However, the company's product revenue showed a growth tre.
In the first half of the year, its product revenue reached 561 million US dollars, an increase of 133% compared with the same period last ye.
In the second quarter alone, product revenue reached $305 million, a 120% increase from the same period a year earli.
The company stated that the increase in product revenue was mainly due to the increase in sales of its self-developed products Baiyueze (zanubrutinib capsules) and Baizean (tislelizumab injectio.
According to the data, BeiGene is a global biotechnology company focused on the development and commercialization of innovative anti-tumor drugs, aiming to improve treatment outcomes and drug accessibility for patients around the wor.
Cinda Bio: Up over 5% As of 10:35, Cinda Bio has risen by 78%, with a quotation of HK$3750, a turnover of 465 million, a turnover rate of 90%, and a loss of T.
In the news, Innovent announced on August 4 that the company and Sanofi Group have reached a multi-project strategic cooperation to carry out the clinical development and commercialization of two high-potential anti-tumor drugs SAR408701 and SAR444245 in Chi.
At the same time, it was announced that in the second quarter of 2022, the company's total product revenue exceeded RMB 1 billion, and the approved commercial product portfolio continued to grow in volu.
According to the data, Innovent is a biopharmaceutical company dedicated to the research and development, production and sales of innovative drugs in the fields of oncology, autoimmunity, metabolism and ophthalmolo.
"Begins with faith, achieves in action", and developing high-quality biological drugs affordable to the common people is the ideal and goal of Innovent B.
GenScript Biotechnology: Up over 5% As of 10:35, GenScript Biotechnology increased by 23%, with a quotation of HK$3200, a turnover of 114 million, a turnover rate of 18%, and a loss in price-earnings (TT.
In the news, GenScript announced that Legend Bio, a non-wholly-owned subsidiary of the company, appointed .
Zhang Fangliang, .
Mao Li and .
Tomas.
Heyman as new directors of Legend Bio's board of directors, effective August 2, 202
According to the data, GenScript is an important life science R&D and production service provider in the wor.
It is an international biotechnology company whose business covers life science services, biopharmaceutical CDMO, cell therapy and industrial synthetic biological produc.
"Using biotechnology to make people and nature healthier", its business operations have covered more than 140 countries and regions around the world, providing services and products to more than 180,000 custome.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
As of 10:35, BeiGene rose by more than 11%, Innovent Bio and GenScript Biotechnology rose by more than 5%, and China Biopharmaceutical and CSPC Group followed su.
BeiGene: Up more than 11% As of 10:35, BeiGene increased by 105%, with a quotation of 1199 yuan, a turnover of 421 million, a turnover rate of 79%, and a loss in price-earnings (TT.
On the news, BeiGene released the US stock performance report for the second quarter of 2022 and the A-share semi-annual performance report on August The semi-annual report shows that in the first half of this year, the company achieved a total operating income of 21 billion yuan, a year-on-year decrease of 19%; the net profit attributable to owners of the parent company was still at a loss, reaching 664 billion yuan; the operating loss was 43 billion yuan, an increase over the same period last ye.
063 billion yu.
As for the reasons for the expansion of operating losses, the company stated that it was mainly due to the decline of 774 billion yuan in cooperation income and the exchange loss of 771 million yuan due to the appreciation of the US doll.
The former was mainly due to the same period last ye.
Partial revenue recognition for USD cooperative advanc.
However, the company's product revenue showed a growth tre.
In the first half of the year, its product revenue reached 561 million US dollars, an increase of 133% compared with the same period last ye.
In the second quarter alone, product revenue reached $305 million, a 120% increase from the same period a year earli.
The company stated that the increase in product revenue was mainly due to the increase in sales of its self-developed products Baiyueze (zanubrutinib capsules) and Baizean (tislelizumab injectio.
According to the data, BeiGene is a global biotechnology company focused on the development and commercialization of innovative anti-tumor drugs, aiming to improve treatment outcomes and drug accessibility for patients around the wor.
Cinda Bio: Up over 5% As of 10:35, Cinda Bio has risen by 78%, with a quotation of HK$3750, a turnover of 465 million, a turnover rate of 90%, and a loss of T.
In the news, Innovent announced on August 4 that the company and Sanofi Group have reached a multi-project strategic cooperation to carry out the clinical development and commercialization of two high-potential anti-tumor drugs SAR408701 and SAR444245 in Chi.
At the same time, it was announced that in the second quarter of 2022, the company's total product revenue exceeded RMB 1 billion, and the approved commercial product portfolio continued to grow in volu.
According to the data, Innovent is a biopharmaceutical company dedicated to the research and development, production and sales of innovative drugs in the fields of oncology, autoimmunity, metabolism and ophthalmolo.
"Begins with faith, achieves in action", and developing high-quality biological drugs affordable to the common people is the ideal and goal of Innovent B.
GenScript Biotechnology: Up over 5% As of 10:35, GenScript Biotechnology increased by 23%, with a quotation of HK$3200, a turnover of 114 million, a turnover rate of 18%, and a loss in price-earnings (TT.
In the news, GenScript announced that Legend Bio, a non-wholly-owned subsidiary of the company, appointed .
Zhang Fangliang, .
Mao Li and .
Tomas.
Heyman as new directors of Legend Bio's board of directors, effective August 2, 202
According to the data, GenScript is an important life science R&D and production service provider in the wor.
It is an international biotechnology company whose business covers life science services, biopharmaceutical CDMO, cell therapy and industrial synthetic biological produc.
"Using biotechnology to make people and nature healthier", its business operations have covered more than 140 countries and regions around the world, providing services and products to more than 180,000 custome.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
